Buscar
NeOnc Technologies Holdings Inc
NTHIAñadir a la lista de seguimiento
3.490USD
0.0000.00%
Cierre 07-31 16:00（ET）Cotizaciones retrasadas 15 min
76.75MCap. mercado
PérdidaP/E TTM
Más Datos de NeOnc Technologies Holdings Inc Compañía
NeOnc Technologies Holdings, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on establishing treatments for intracranial malignancies, such as aggressive cancers located in the brain. It is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. It is developing novel drug delivery methods to be used in combination with novel drug candidates. The Company has two lead products in development: NEO100 and NEO212. NEO100 is a purified form of perillyl acid (POH) which is administered to brain cancer patients via intranasal delivery. NEO212 is a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol. NEO212 is undergoing development towards intranasal application specifically for patients with uncontrolled brain metastases derived from peripheral tumors (lung, breast, skin, and others).
Información de NeOnc Technologies Holdings Inc
Símbolo de cotizaciónNTHI
Nombre de la empresaNeOnc Technologies Holdings Inc
Fecha de salida a bolsaMar 26, 2025
Director ejecutivoHeshmatpour (Amir F)
Número de empleados- -
Tipo de seguridadOrdinary Share
Fin del año fiscalMar 26
Dirección23975 Park Sorrento
CiudadCALABASAS
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal91302
Teléfono13106637831
Sitio Webhttps://neonc.com/
Símbolo de cotizaciónNTHI
Fecha de salida a bolsaMar 26, 2025
Director ejecutivoHeshmatpour (Amir F)
Ejecutivos de NeOnc Technologies Holdings Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Bader Almonawer
Mr. Bader Almonawer
Lead Independent Director
Lead Independent Director
50.16K
--
Dr. Steven L. Giannotta, M.D.
Dr. Steven L. Giannotta, M.D.
Independent Director
Independent Director
50.16K
--
Dr. Victoria Medvec, Ph.D.
Dr. Victoria Medvec, Ph.D.
Independent Director
Independent Director
--
--
Hon. Jim Delshad
Hon. Jim Delshad
Independent Director
Independent Director
--
--
Ms. Laurie Berman
Ms. Laurie Berman
Investor Relations
Investor Relations
--
--
Mr. Josh Neman
Mr. Josh Neman
Chief Clinical Officer
Chief Clinical Officer
--
--
Dr. Thomas C. Chen, M.D., Ph.D.
Dr. Thomas C. Chen, M.D., Ph.D.
Chief Medical Officer, Chief Scientific Officer, Director
Chief Medical Officer, Chief Scientific Officer, Director
--
--
Mr. Keithly A. Garnett
Mr. Keithly A. Garnett
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Amir F. Heshmatpour
Mr. Amir F. Heshmatpour
Executive Chairman of the Board, President, Chief Executive Officer
Executive Chairman of the Board, President, Chief Executive Officer
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Bader Almonawer
Mr. Bader Almonawer
Lead Independent Director
Lead Independent Director
50.16K
--
Dr. Steven L. Giannotta, M.D.
Dr. Steven L. Giannotta, M.D.
Independent Director
Independent Director
50.16K
--
Dr. Victoria Medvec, Ph.D.
Dr. Victoria Medvec, Ph.D.
Independent Director
Independent Director
--
--
Hon. Jim Delshad
Hon. Jim Delshad
Independent Director
Independent Director
--
--
Ms. Laurie Berman
Ms. Laurie Berman
Investor Relations
Investor Relations
--
--
Mr. Josh Neman
Mr. Josh Neman
Chief Clinical Officer
Chief Clinical Officer
--
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de NeOnc Technologies Holdings Inc?
Los cinco principales accionistas de NeOnc Technologies Holdings Inc son: Mr. Bader Almonawer